United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

30 Sep 2016
Change (% chg)

¥-26 (-1.66%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Thu, Sep 29 2016

BRIEF-Cytokinetics announces early termination of Hart-Scott-Rodino waiting period

* Announces Early Termination Of Hart-Scott-Rodino waiting period for expanded collaboration with astellas

BRIEF-Astellas Pharma gets approval for medicine for hyperphosphatemia in Japan

* Says the co received a marketing approval of Kiklin Granules 86.2% for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease in Japan

Astellas, Vical herpes vaccine fails mid-stage study

Japan's Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.

BRIEF-Vical and Astellas study on CMV vaccine fails to meet its primary endpoint

* Results from study demonstrated that trial did not meet its primary endpoint

BRIEF-R&I affirms Astellas Pharma's rating at "AA" and says stable outlook - R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" - R&I

BRIEF-Astellas Pharma submits new drug application for extended-release tablets of quetiapine fumarate in Japan

* Says it submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder

BRIEF-Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration

* Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration

BRIEF-Astellas Pharma unit to sell Astellas Pharma Technologies to Avara

* Says its unit to sell Astellas Pharma Technologies, Inc. to Avara Norman Pharmaceutical Services, Inc (Avara) on Aug. 4 (U.S time)

BRIEF-Astellas to transfer U.S. manufacturing unit to Avara

* Astellas announces transfer of U.S. manufacturing subsidiary to Avara

BRIEF-Cytokinetics Inc reports q2 2016 financial results

* Will not update financial guidance until Q3 earnings due to recent expansion of collaboration with Astellas

Select another date: